High levels of β2M are an important prognostic factor and included in the ISS for MM: β2M less than 3.5 mg/L indicates Stage I, whereas levels ≥ 5.5 mg/L indicate Stage III. This evidence concerns the gene B2M and Miyoshi myopathy.